Skip to Main content Skip to Navigation
Journal articles

[The patient with uncontrolled chronic hepatitis B]

Abstract : The treatment of chronic hepatitis B is now based on the using of pegylated interferon or nucleoside or nucleotide analogs. In the majority of cases, these drugs can control viral replication with an hepatitis B virus (HBV) DNA negativation after approximately 6 months of therapy. In case of primary non response, it is necessary to modify antiviral therapy and if resistance appears to combine a nucleoside and a nucleotide analog. In patients treated by nucleoside analog, if HBV DNA is not negative or do not dramatically decreases at the week 24, it is also necessary to add a nucleotide analog. However, for adefovir therapy, it is usually preferable to wait at week 48. In summary, a regular following every 3 months of HBV DNA detection by a sensitive method (Real Time PCR) allows to evaluate the therapeutic efficacy and to prevent the risk of biochemical and clinical rebound due to appearance of resistance mutations.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00324943
Contributor : Alain Duperray <>
Submitted on : Thursday, September 25, 2008 - 4:57:30 PM
Last modification on : Wednesday, January 10, 2018 - 10:12:02 AM

Identifiers

Collections

U823 | UGA

Citation

Jean-Pierre Zarski, Vincent Leroy. [The patient with uncontrolled chronic hepatitis B]. Gastroentérologie Clinique et Biologique / Research and Clinics in Hepatology and Gastroenterology, Elsevier Masson, 2008, 32 (1 Pt 2), pp.S7-11. ⟨10.1016/S0399-8320(08)73259-7⟩. ⟨inserm-00324943⟩

Share

Metrics

Record views

74